Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Reply to ‘Rituximab in CD20 positive multiple myeloma’ by P Moreau et al.

Leukemia volume 22, pages 214–215 (2008)Cite this article

We read with interest the Phase II study of Moreau et al.,1 evaluating four weekly infusions of single-agent rituximab (375 mg/m2) therapy in a cohort of patients with CD20+ multiple myeloma (MM) with either stage I, never treated disease, or stage III MM in relapse, or refractory after two lines of therapy. The authors concluded that rituximab as a single agent had minor activity in this cohort of patients with CD20 expression on at least 33% of tumor cells.

Although the authors did not observe a major impact of rituximab therapy in MM, we would like to draw attention to one patient in their study with 100% CD20 expression who experienced an ongoing 18 month minor response, in contrast to the other patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Moreau P, Voillat L, Benboukher L, Mathiot C, Dumontet C, Robillard N et al. Rituximab in CD20 positive multiple myeloma. Leukemia 2007; 21: 835–836.

    Article  CAS  Google Scholar 

  2. Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003; 102: 1070–1071.

    Article  CAS  Google Scholar 

  3. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103: 2332–2336.

    Article  CAS  Google Scholar 

  4. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002; 99: 3735–3741.

    Article  CAS  Google Scholar 

  5. Robillard N, Wuilleme S, Lode L, Magrangeas F, Minvielle S, Avet-Loiseau H . CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target. Leukemia 2005; 19: 2021–2022.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Medicine Program, Mayo Clinic, Rochester, MN, USA

    P T Greipp

  2. Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

    P Kapoor, T E Witzig & P R Greipp

  3. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

    W G Morice

Authors
  1. P T Greipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Kapoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W G Morice
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T E Witzig
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P R Greipp
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P T Greipp.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Greipp, P., Kapoor, P., Morice, W. et al. Reply to ‘Rituximab in CD20 positive multiple myeloma’ by P Moreau et al.. Leukemia 22, 214–215 (2008). https://doi.org/10.1038/sj.leu.2404972

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404972

Search

Advanced search

Quick links